80% of breast cancer patients are affected by TOP2. Herceptin by Roche which helps 20% of breast cancer patients earns them $6 billion. SBFM has the science to deal with the TQP2 issue and a Patent on it. It is my third largest holding after CLSN and CTIX. It is a PRIMARY MEMBER of the Magnificent Seven and deserves to be. The current share price is a JOKE and does not reflect the value of the companys assets